NCT06313801 2025-11-21
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Nizhny Novgorod Regional Clinical Oncology Center
Phase 2 Recruiting
Clinical Trials
24 trialsNCT07136974 2025-08-22
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07050043 2025-07-03
LEDANG
Hospital Sultanah Bahiyah
Phase 3 Recruiting
NCT06927180 2025-06-23
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Henan Cancer Hospital
Phase 2 Recruiting
NCT03914443 2025-05-31
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase 1 Completed
NCT05475678 2025-01-23
Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05878028 2024-05-23
L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC
Henan Cancer Hospital
Phase 2 Recruiting
NCT05474690 2024-02-26
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
Henan Cancer Hospital
Phase 3 Withdrawn
NCT06208033 2024-01-17
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Phase EARLY_PHASE1 Unknown
NCT00268476 2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3 Active not recruiting
NCT03735966 2022-12-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Henan Cancer Hospital
Phase 2 Completed
NCT05192681 2022-01-14
Tislelizumab as Cross-line Treatment for Advanced NSCLC
Fujian Cancer Hospital
Phase 2 Unknown
NCT04351867 2020-07-16
A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer
Henan Cancer Hospital
Phase 3 Unknown
NCT03497702 2018-04-13
NeoChAI
National Cancer Center, Korea
Phase 2 Unknown
NCT01472146 2017-05-09
ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Instituto Nacional de Cancer, Brazil
Phase 2 Completed
NCT03137004 2017-05-08
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT01356303 2016-05-13
TAXIS01
National Guard Health Affairs
Phase 2 Suspended
NCT01380275 2014-09-25
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Phase 2 Unknown
NCT01356368 2014-01-22
Customizing
National Guard Health Affairs
Phase 2 Terminated
NCT01442909 2011-09-29
Pemetrexed Followed by Docetaxel or in Reverse Sequence
Taipei Veterans General Hospital, Taiwan
Phase 4 Completed
NCT00352378 2011-06-27
Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer
National Cancer Center, Korea
Phase 3 Completed
NCT01331928 2011-04-08
Sequential Chemotherapy With Xelox Follows by TX to Treat Gastric Cancer
Taipei Veterans General Hospital, Taiwan
Phase 2 Unknown
NCT00980382 2009-09-21
A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma
National Cancer Center, Korea
Phase 1/2 Completed
NCT00980603 2009-09-21
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown